Development of a Conceptual Marketing Model for Medicinal Products for Rare Diseases

6th International Scientific Conference – EMAN 2022 – Economics and Management: How to Cope With Disrupted Times, Ljubljana, Slovenia, March 24, 2022, CONFERENCE PROCEEDINGS, published by: Association of Economists and Managers of the Balkans, Belgrade, Serbia; ISBN 978-86-80194-57-8, ISSN 2683-4510

Abstract:

Health is a basic human value and we cannot and should not set a price on it, but we can try to understand its value through the prism of morality, ethics, science and human connections. Health cannot be evaluated through the prism of moral principles (is a person good or bad, is he worth helping, is his contribution to society big enough for society to take care of him…). . Some individuals struggle with incurable diseases from birth and spend their entire lives searching for that piece of help or solution that would alleviate their suffering and pain and enable them to live a dignified life.

The purpose of the article is to present the design for the development of a conceptual model, which will be the basis for subsequent empirical testing and the development of a marketing model for the entry of an orphan drug into the market, developed with the implementation of established marketing approaches and insights gained in qualitative research with a con­structivist approach, and a designed marketing strategy that will follow the legislative and ethical principles required for the marketing of medicinal products

Keywords:

Conceptual marketing model; Medicinal product; Health technologies assessment; Orphan drug;
Constructivist grounded theory

REFERENCES

Abramson, J. 2004. Overdosed America: The Broken Promise of American Medicine. New York, NY: HarperCollins.

Anamul, Z. 2011. Business Analysis of Pharmaceutical Firms in Bangladesh: Problems and Prospects. Journal of Business and Technology (Dhaka), 6(1).

Angeli, M. 2004. The Truth About the Drug Companies: How They Deceive Us and What To Do About It. New York, NY: Random House.

Beauchamp, T.L. in Childress J.F. 2008. Principles of Biomedical Ethics (6 izd.). New York, NY: Oxford University Press.

Birks, M. in Mills, J. 2015. Grounded Theory (2 edition). Los Angeles. Sage Publications Ltd.

Brody, H. 2021. The Ethics of Drug Development and Promotion: The Need for a Wider Medi­cal Care, Vol. 50, No. 11, str. 910-912.

Charmaz, K. 2000. Constructivist and objectivist grounded theory. V N. K. Denzin in Y. Linco­ln (Eels.), Handbook of Qualitative Research (2nd ed., str. 509-535). Thousand Oaks. Sage.

Charmaz, K. 2014. Constructing Grounded Theory: A Practical Guide Through Qualitative Analysis (2 izd.). London: Sage.

Deyo, R.A, in Patrick D.L. 2005. Hope or Hype: The Obsession With Medical Advances and the High Cost of False Promises. New York, NY: AMACOM, American Management Association

Glaser, B.G. 2001. The grounded theory perspective: Conceptualization contrasted with description. Mill Valley, CA: Sociology Press.

Glaser, B.G. in Strauss, A. L. 1967. The Discovery of Grounded Theory: Strategies for Qualita­tive Research. Chicago. Aldine.

Kesič, D. 2004. Model tržnega prilagajanja farmacevtskih družb iz tranzicijskih držav v proce­su globalizacije trga (doktorska disertacija). Ekonomska fakulteta, Maribor

Kotler, P. in Keller, K. 2016. Marketing Management (15. izd.). New Jersey: Pearson Educati­on Limited.

Murphy, C., Klotz, A.C. in Kreiner, G.E. 2017. Blue skies and black boxes: the promise (and pra­ctice) of grounded theory in human resource management research. Human Resource Ma­nagement Review, 27, 291–305.

Smith, R. 2005. Medical journals are an extension of the marketing arm of pharmaceutical com­panies. PLoS Med. 2005;2:el38.

Spurling, GK. Mansfield PR. Montgomery BD. Lexchin J. Doust J. Othman N. idr. 2010. Infor­mation from Pharmaceutical Companies and the Quality, Quantity, and Cost of Physici­ans‘ Prescribing: A Systematic Review. PLoS Med 7(10): e1000352.

Szegedi, M., Zelei, T., Arickx, F. in et al. 2018. The European challenges of funding orphan me­dicinal products. Orphanet J Rare Dis 13, 184.

Timonen, V., Foley, G. in Conlon, C. 2018. Challenges when using grounded theory: a pragma­tic introduction to doing GT research. International Journal of Qualitative Methods, 17, 1–10.

Watt, H. 2015. Life and Health: A Value in Itself for Human Beings?. HEC Forum. 27:207–228

Elektronski viri

»About orphan drugs«, ORPHANET (2020). Elektronski vir: https://www.orpha.net/consor/cgi-bin/Education_AboutOrphanDrugs.php?lng=EN. [Dostop: 4.1.2020]

»Tools and methodologies to assess the efficiency of health care services in Europe«, European Commission, (2019). Elektronski vir: https://ec.europa.eu/health/sites/health/files/systems_ performance_assessment/docs/2019_efficiency_en.pdf, . [Dostop: 4.1.2020].

Anderson R. 2014. BBC News – Pharmaceutical industry gets high on fat profits. 19 November 2014. https://www.bbc.com/news/business-28212223. [Dostop: 28. 4. 2021]

European Medicines Agency, Legal framework: orphan designation. Elektronski vir: https: //www. ema.europa.eu/en/human-regulatory/overview/orphan-designation/legal-framework-or­phan-designation. [Dostop: 8.3.2021]

JAZMP. 2021, Elektronski vir: https://www.jazmp.si/humana-zdravila/hta/. [Dostop: 19.4.2021]

ZZZS. 2020. Razvrščanje zdravil na listo. https://partner.zzzs.si/wps/portal/portali/aizv/zdra­vila_in_zivila_za_posebne_zdravstvene_namene/razvrscanje_zdravil_in_zivil_na_listo/ razvrscanje_zdravil_na_listo (1. 2. 2020)